Abstract: A method for quantifying the activity of the proteins/enzymes involved in the conjugation of the SUMO/Ubiquitin/Nedd8 proteins in a cell of a biological sample the method including: a) a step of contacting a cellular extract of cell with each protein of a subgroup of at least 3 proteins wherein the at least 3 proteins corresponds to the proteins essentially including or only including the sequences SEQ ID NO: 1 to 3, b) a step of simultaneously measuring ubiquitination, sumoylation and neddylation level of each of the at least 3 proteins to obtain a first value for ubiquitin, SUMO and Nedd8.

Abstract: A method for quantifying the activity of the proteins/enzymes involved in the conjugation of the SUMO/Ubiquitin/Nedd8 proteins in a cell of a biological sample the method including: a) a step of contacting a cellular extract of cell with each protein of a subgroup of at least 3 proteins wherein the at least 3 proteins corresponds to the proteins essentially including or only including the sequences SEQ ID NO: 1 to 3, b) a step of simultaneously measuring ubiquitination, sumoylation and neddylation level of each of the at least 3 proteins to obtain a first value for ubiquitin, SUMO and Nedd8.

Abstract: Method of cancer treatment by controlling cellular p53 protein levels. The invention concerns, in particular, the use of a compound capable of modulating calpaine activity.

Abstract: Method of cancer treatment by controlling cellular p53 protein levels. The invention concerns, in particular, the use of a compound capable of modulating calpaine activity.

Abstract: Method of cancer treatment by controlling cellular p53 protein levels. The invention concerns, in particular, the use of a compound capable of modulating calpaine activity.

Abstract: The invention concerns a biological material for preparing a pharmaceutical composition for treating a mammal by gene transfer, comprising, either at least a nucleic acid sequence containing a therapeutic gene and in a form enabling in vivo transfer of said gene into the cells of the mammal, or at least one cell of the mammal not naturally producing antibodies, genetically modified in vitro by at least a previous nucleic acid sequence, and in a form enabling its incorporation into the organism of the mammal as well as optionally its previous culture. The invention is characterized by the fact that said nucleic acid sequence contains an antibody gene and elements for expressing in vivo said antibody gene and the secretion in the blood circulation of a mammal of a therapeutically effective amount of this antibody or a fragment of it, by cells of said mammal genetically modified by said nucleic acid sequence and not naturally producing antibodies.

Abstract: The present invention relates to capsules encapsulating antibody-producing cells, and to use of such capsules and encapsulated cells, respectively, for implantation in vivo for long term delivery or sustained delivery of antibodies of therapeutic interest.